Actively Recruiting

Age: 18Years +
All Genders
ID06714799

Analysis of Videodermatoscopic Parameters of Ocular, Periocular, Conjunctival and Palpebral Neoformations

Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2024-12-05

300

Participants Needed

1

Research Sites

208 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to analyze videodermatoscopic features of neoformations located in and around the eye, including ocular, periocular, conjunctival, and eyelid areas. It uses advanced videodermatoscopy technology to closely examine these lesions, assessing characteristics like size, shape, color, and internal structure. The goal is to help differentiate benign neoformations from those that may need further diagnosis or treatment. Participants with various ocular and periocular neoformations such as melanocytic nevus, seborrheic keratosis, angioma, basal cell carcinoma, melanoma, and others will be observed. This is an observational study without drug or device interventions. The analysis focuses on monitoring features that could suggest whether the neoformations are benign or malignant from enrollment until the end of 2026. During the study, participants will undergo detailed videodermatoscopic examinations to collect data on the lesions. Researchers will evaluate the features of these neoformations over time to distinguish their nature. The study involves regular assessments and does not include treatment. Participation may last up to several years to monitor lesion characteristics and outcomes.

CONDITIONS

Brief Title

Analysis of Videodermatoscopic Parameters of Ocular, Periocular, Conjunctival and Palpebral Neoformations

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients diagnosed with one or more of the following eye or periocular conditions: common melanocytic nevus, melanosis, seborrheic keratosis, viral wart, angioma, angiokeratoma, apocrine hydrocystoma, xanthelasma, steatocystoma, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, or melanoma.
  • Age 18 years or older.
Not Eligible

You will not qualify if you...

  • Patients with inflammatory eye conditions such as blepharitis, chalazion, pterygium, or pinguecula.
  • Patients with multiple periocular or ocular lesions.
  • Patients diagnosed with syndromic diseases associated with a high risk for skin neoformations.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Diagnostic Evaluation

Duration - From enrollment to the end of 2026

Participants undergo videodermatoscopic examination to assess ocular and periocular lesions in detail, evaluating characteristics such as size, shape, color, and internal structure.

Long-term Monitoring

Duration - Until the end of 2026

Participants are observed over time to identify features indicating benign or malignant nature of the lesions.

Trial Site Locations

Total: 1 location

1

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, Italy, 40138

Actively Recruiting

Loading map...

Research Team

S

Sabina Vaccari, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

Clinical Application Research of Scleral Lenses in Ocular Su...

Ocular Surface Disease

Actively Recruiting

1 location

Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and...

Ocular Surface Disease

Actively Recruiting

1 location

Establishment of a Multimodal Standard Database for Inflamma...

Ocular Surface Disease

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here